1.
Zhonghua Nei Ke Za Zhi
; 55(11): 875-877, 2016 Nov 01.
Artigo
em Zh
| MEDLINE
| ID: mdl-27801345
RESUMO
In 12 patients with relapsed or refractory acute myelogenous leukemia (AML), the efficacy and safety of a novel regimen, namely thalidomide combined with interferon and interleukin 2 (IL-2), were initially explored.All the patients have received the triple-drug regimen for at least one cycle.Three patients achieved incomplete remission (CRi), 3 patients with partial remission.The overall response rate (ORR) was 50%.